Julie Cooke

NBIX CHRO Julie Cooke sells 36,937 shares across 5 transactions for $5,770,235.26 under 10b5-1 plan

Julie Cooke, Chief Human Resources Officer at Neurocrine Biosciences, executed 5 separate sales on 2026-06-02 totaling 36,937 shares for $5,770,235.26 at a blended average price of $156.22, reducing her non-derivative holdings to 22,374 shares. This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2026-03-03, meaning the timing and execution were scheduled rather than discretionary. Notably, Cooke's same-ticker history at NBIX shows mixed outcomes on her prior 4 sales at this company, with results ranging from -18.9% to +1.0% over 90 days where measurable. The stock currently trades at $167.35, reflecting a 30-day appreciation of 23.9% and 90-day gain of 30.6%, positioned near its 52-week high of $165.81.

Cooke (CHRO) sold 12,632 shares of NBIX at $153.26 (Aug 1); stock now $147.70, -3.6% from 52-week high

Julie Cooke, Chief Human Resources Officer, sold 12,632 shares of Neurocrine Biosciences on 2024-08-01 at $153.26, reducing her holding from 30,834 to 18,202 shares (-41.0%). The sale occurred near the stock's 52-week high of $153.15, with current price at $147.70. At same-ticker NBIX, Cooke's prior three measurable sales (including two on 2023-12-22 and one on 2023-05-01) showed mixed timing: two generated gains at the 90-day mark (+10.6%, +13.4%), while one resulted in a loss (-1.1%), yielding 1 of 3 well-timed outcomes. Her cross-ticker track record across all tickers shows 4 prior sells with a 90-day well-timed rate of 33.33%, suggesting below-average execution of sell timing historically. The current position—a large reduction executed at peak valuation in a company with strong 26.8% annual revenue growth and $14.9B market cap—warrants observation as to whether subsequent price action aligns with or diverges from her historical patterns.

CHRO Julie Cooke sold 10,000 NBIX shares at $140.19 (July 2024); reduced holdings by 35.5%

Julie Cooke, Chief Human Resources Officer, executed a single open-market sale of 10,000 shares at $140.19 on 2024-07-01, reducing her holdings by 35.5% to 18,202 shares. Her cross-ticker track record shows 3 prior open-market sales with a 90-day well-timed rate of 33.33%, indicating mixed execution; at this specific ticker (NBIX), her prior 3 sales showed negative 90-day returns in only 1 of 3 cases (33% well-timed at the 90-day mark). The current share price of $137.49 stands 4.4% below the 52-week high of $143.74, and the 30-day and 90-day price changes are modest (+1.5% and -0.1% respectively). The company's fundamentals remain strong—annual revenue growth of +26.8%, net income of $43,400,000.00, and a market cap of $13,836,612,340.23—though the P/E of 37.46 reflects a premium valuation. The timing and magnitude of this sale offer no clear directional signal about CHRO confidence in near-term stock direction.